cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Nuvalent Inc
3 own
3 watching
Current Price
$44.59
$2.09
(4.92%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
939.32M
52-Week High
52-Week High
44.61
52-Week Low
52-Week Low
8.505
Average Volume
Average Volume
0.42M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization939.32M
icon52-Week High44.61
icon52-Week Low8.505
iconAverage Volume0.42M
iconDividend Yield--
iconP/E Ratio--
What does the Nuvalent Inc do?
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Nuvalent Inc make?
News & Events about Nuvalent Inc.
PR Newswire
1month ago
Nuvalent Presents New Preclinical Data Supporting Intracranial Activity of NVL-655 at AACR Annual Meeting 2023 Nuvalent Presents New Preclinical Data Supporting Intracranial Activity of NVL-655 at AACR Annual Meeting 2023 PR Newswire CAMBRIDGE, Mass., April 18, 2023 CAMBRIDGE, Mass., April 18, 2023...
PR Newswire
5 months ago
Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520 Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520 PR Newswire CAMBRIDGE, Mass., Dec. 13, 2022...
PR Newswire
7 months ago
Nuvalent Announces Closing of Upsized Public Offering of Common Stock Nuvalent Announces Closing of Upsized Public Offering of Common Stock PR Newswire CAMBRIDGE, Mass., Nov. 3, 2022 CAMBRIDGE, Mass., Nov. 3, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical...
PR Newswire
7 months ago
Nuvalent Announces Pricing of Public Offering of Common Stock Nuvalent Announces Pricing of Public Offering of Common Stock PR Newswire CAMBRIDGE, Mass., Oct. 31, 2022 CAMBRIDGE, Mass., Oct. 31, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused...
PR Newswire
7 months ago
Nuvalent Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients withROS1-Positive NSCLC Nuvalent Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients...
Frequently Asked Questions
Frequently Asked Questions
What is Nuvalent Inc share price today?
plus_minus_icon
Can Indians buy Nuvalent Inc shares?
plus_minus_icon
How can I buy Nuvalent Inc shares from India?
plus_minus_icon
Can Fractional shares of Nuvalent Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Nuvalent Inc stocks?
plus_minus_icon
What is today’s traded volume of Nuvalent Inc?
plus_minus_icon
What is today’s market capitalisation of Nuvalent Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Nuvalent Inc?
plus_minus_icon
What percentage is Nuvalent Inc down from its 52-Week High?
plus_minus_icon
What percentage is Nuvalent Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$44.59
$2.09
(4.92%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00